Karen Lynn (Riedl) Reckamp MD MS
Thoracic Cancer
Director, Division of Medical Oncology Associate Director, Clinical Research, Cedars-Sinai Cancer
Join to View Full Profile
8700 Beverly BlvdLos Angeles, CA 90048
Phone+1 310-423-7197
Dr. Reckamp is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Karen Reckamp is an oncologist in Los Angeles, CA and is affiliated with Cedars-Sinai Medical Center. She received her medical degree from University of Chicago Pritzker School of Medicine and has been in practice over 15 years. She specializes in hematologic oncology and thoracic cancer and is experienced in lung cancer, thymic malignancies and mesothelioma.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
- PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
- Ponatinib in Advanced NSCLC w/ RET Translocations Start of enrollment: 2013 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients.Philip C Mack, James M Crawford, Andres Chang, Anna Yin, Sabra L Klein
Journal of the National Cancer Institute. 2025-03-24 - CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer.Manish Thiruvalluvan, Sandrine Billet, Zhenqiu Liu, Joseph Lownik, Barliz Waissengrin
Drug Resistance Updates. 2025-03-12 - Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?Kamya Sankar, Karen L Reckamp
Lancet. 2025-03-08
Lectures
- Germline mutations and onset of lung adenocarcinoma in smokers and nonsmokers.2019 ASCO Annual Meeting - 6/1/2019
- Brigatinib for Metastatic ALK Positive Non-Small Cell Lung Cancer. FDA Approvals and Their Incorporation into Clinical Practice2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Authored Content
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Press Mentions
Cedars-Sinai Experts Present Research at Annual Oncology MeetingApril 21st, 2025- A Closer Look at the Innovative Pragmatica-Lung TrialJuly 30th, 2024
- Non-Small Cell Lung Cancer | Karen Reckamp, MD, MSJune 12th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
